Alzheimer’s disease is a progressive brain disease that destroys memory, thinking ability, and eventually the capacity to carry out basic tasks. It is the most common type of dementia, accounting for the majority of dementia cases worldwide. Dementia itself is not a single disease but an umbrella term for a decline in mental ability severe enough to interfere with daily life. Alzheimer’s is one specific cause of that decline, with a distinct pattern of brain changes that sets it apart from other forms.
What Happens Inside the Brain
Alzheimer’s involves two types of abnormal protein buildup in the brain. The first is amyloid plaques, sticky clumps of protein fragments that accumulate between nerve cells. The second is tau tangles, twisted fibers of another protein that form inside neurons. Both interfere with how brain cells communicate and survive, but they do so in different ways.
Amyloid buildup appears to come first. Even before symptoms begin, small, soluble clumps of amyloid collect at the junctions where neurons pass signals to each other. These clumps disrupt signaling between cells and are closely associated with the earliest cognitive decline. Over time, they appear to trigger a cascade that causes tau protein to become abnormally modified and spread from cell to cell.
Tau tangles do their damage from inside the neuron. Tau normally helps maintain the internal scaffolding that transports nutrients and other materials through nerve cells. When tau becomes tangled, that transport system collapses. The neuron can no longer function properly and eventually dies. As more neurons die, entire brain regions begin to shrink.
The hippocampus, the brain’s memory center, is one of the first areas affected. Research has shown that specific parts of the hippocampus begin shrinking even in people who appear cognitively normal, years before any clinical symptoms emerge. This early, invisible atrophy explains why memory loss is typically the first noticeable sign of the disease. As Alzheimer’s progresses, the damage spreads to regions responsible for language, reasoning, spatial awareness, and eventually basic physical functions like swallowing and movement.
Symptoms at Each Stage
Alzheimer’s typically moves through a recognizable progression, though the pace varies significantly from person to person.
Mild cognitive impairment (MCI): The earliest stage involves subtle memory lapses, like forgetting recently learned information, misplacing things, or repeating questions. People at this stage can still work and maintain relationships. They may struggle to estimate how long a task will take or to plan the steps needed to complete something. Decision-making becomes slightly harder. Not everyone with MCI goes on to develop Alzheimer’s, but it is often the first detectable sign.
Mild dementia: This is the stage where Alzheimer’s is most commonly diagnosed. Memory gaps become more consistent and harder to brush off. People may get lost in familiar places, have trouble managing finances, or struggle to find the right words in conversation. Personality changes can appear, including withdrawal from social activities or increased anxiety.
Moderate dementia: Confusion deepens. People may not recognize family members or may become convinced of things that aren’t true, such as accusing a partner of infidelity. Some experience hallucinations. Restlessness and agitation are common, particularly in the late afternoon and evening. Outbursts of aggressive behavior can occur. At this stage, people typically need help with daily activities like dressing and bathing.
Severe dementia: In the final stage, mental function declines profoundly and physical abilities deteriorate alongside it. People lose the ability to communicate, to sit upright without support, and to control bladder and bowel functions. Muscles become rigid. Eventually, the ability to swallow is lost. Death most often results from complications like pneumonia or infection rather than from the disease itself.
Risk Factors You Can and Can’t Control
Age is the strongest risk factor for Alzheimer’s. Most people diagnosed are 65 or older, and risk roughly doubles every five years after that. Genetics also play a role. A gene variant called APOE-e4 increases risk and is associated with earlier onset. Carrying two copies of this variant raises risk further than carrying one. However, having the gene does not guarantee the disease, and many people with APOE-e4 never develop Alzheimer’s.
What may surprise many readers is just how much of dementia risk is tied to lifestyle and health conditions that can be managed. A landmark report led by researchers at University College London identified 14 modifiable risk factors that together account for nearly half of all dementia cases worldwide. The biggest contributors include hearing loss, high “bad” cholesterol in midlife, lower levels of education in early life, and social isolation in later life. Other significant factors include high blood pressure, smoking, obesity, physical inactivity, diabetes, excessive alcohol consumption, depression, traumatic brain injury, air pollution, and untreated vision loss. No single factor dominates, but addressing several of them across a lifetime meaningfully lowers overall risk.
How Alzheimer’s Is Diagnosed
There is no single test that confirms Alzheimer’s. Diagnosis typically involves a combination of cognitive assessments, medical history, brain imaging, and increasingly, blood tests that detect the disease’s signature proteins.
One recently approved blood test measures specific forms of tau protein that indicate amyloid plaque buildup in the brain. Studies have shown it is over 90% accurate in detecting Alzheimer’s-related brain changes. The test is currently approved for adults age 50 and older who are already experiencing early memory or thinking problems, such as forgetting names, misplacing items, or repeating questions. It is not yet recommended as a screening tool for people without symptoms, and it cannot diagnose Alzheimer’s on its own. Instead, it serves as one piece of a broader evaluation that includes imaging scans and clinical assessment.
PET scans can also visualize amyloid plaques directly in the brain, providing another layer of confirmation. These advances have made it possible to detect the disease earlier and with more confidence than was possible even a decade ago.
Treatment Options
For most of Alzheimer’s history, available medications could only manage symptoms without slowing the underlying disease. That changed with a new class of treatments: antibody-based drugs designed to clear amyloid plaques from the brain.
The FDA has approved several of these treatments. One, donanemab, works by targeting and removing amyloid plaques. In clinical trials, treatment was adjusted based on how much plaque had been cleared, as measured by PET scans at regular intervals. These drugs represent the first therapies that address one of the root causes of the disease rather than just its symptoms. They are approved for people in the earlier stages of Alzheimer’s, where amyloid removal may do the most good.
These treatments are not cures. They can slow cognitive decline in some patients, but they carry risks including brain swelling and small bleeds that require careful monitoring. Older symptom-management medications remain in use alongside them and can help with memory, confusion, and behavioral changes for a period of time.
What the Timeline Looks Like
Alzheimer’s is a slow disease. The brain changes that cause it begin 15 to 20 years before symptoms appear. Once diagnosed, typically at the mild dementia stage, the progression from early symptoms to severe disability usually spans several years, though the timeline varies widely depending on age at diagnosis, overall health, and individual biology. Some people live with the disease for a decade or more after diagnosis, while others decline more rapidly. The later stages, when physical function deteriorates alongside cognition, tend to progress faster than the earlier ones.